Pieris Pharma Appoints Chief Development Officer
This article was originally published in Scrip
Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel biotherapeutics through its Anticalin technology platform, has named Dr. Louis Matis senior vice-president and chief development officer. Prior to joining Pieris, Matis was, since June 2011, executive director of strategic evaluation at Alexion Pharmaceuticals. He also worked at Alexion from 1993 to 2000, during which time he advanced to the position of chief scientific officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris (eculizumab).
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.